Is RESPIRATORY FAILURE a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed RESPIRATORY FAILURE.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 52 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported RESPIRATORY FAILURE to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and RESPIRATORY FAILURE. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause RESPIRATORY FAILURE, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes RESPIRATORY FAILURE. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if RESPIRATORY FAILURE ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing RESPIRATORY FAILURE: 52
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where RESPIRATORY FAILURE is a reported side effect: 1.5620%

FDA reports of any drug causing RESPIRATORY FAILURE : 29606
Average percentage for all medicated patients where RESPIRATORY FAILURE is reported as a complication: 0.1856%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with RESPIRATORY FAILURE:

HEPARIN SODIUM INJECTION (6184 patients)
ASPIRIN (2642 patients)
LASIX (2261 patients)
PREDNISONE (1750 patients)
PREDNISOLONE (1665 patients)
METHOTREXATE (1509 patients)
VIOXX (1393 patients)
FUROSEMIDE (1316 patients)
REMICADE (1210 patients)
OMEPRAZOLE (1094 patients)
ACETAMINOPHEN (1068 patients)
CYCLOPHOSPHAMIDE (1006 patients)
LISINOPRIL (1004 patients)
FOSAMAX (938 patients)
DEXAMETHASONE (938 patients)
POTASSIUM CHLORIDE (937 patients)
DIGOXIN (934 patients)
FOLIC ACID (931 patients)
COUMADIN (924 patients)
LIPITOR (888 patients)
ALBUTEROL (883 patients)
HEPARIN SODIUM (861 patients)
ALLOPURINOL (849 patients)
NEXIUM (789 patients)
ZOFRAN (765 patients)
MORPHINE (758 patients)
PREDNISONE TAB (737 patients)
ZOMETA (726 patients)
NORVASC (718 patients)
HUMIRA (718 patients)
REVLIMID (703 patients)
LORAZEPAM (703 patients)
PLAVIX (692 patients)
PAXIL (685 patients)
CYCLOSPORINE (682 patients)
PROTONIX (672 patients)
TRACLEER (657 patients)
INSULIN (653 patients)
NEURONTIN (649 patients)
SIMVASTATIN (638 patients)
SYNTHROID (635 patients)
AMBIEN (632 patients)
ATENOLOL (628 patients)
HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% (627 patients)
CARBOPLATIN (619 patients)
HYDROCHLOROTHIAZIDE (614 patients)
SEROQUEL (603 patients)
WARFARIN SODIUM (599 patients)
LEVAQUIN (599 patients)
VANCOMYCIN (597 patients)
FLUOROURACIL (596 patients)
HEPARIN (595 patients)
SPIRIVA (588 patients)
FENTANYL (564 patients)
ATIVAN (558 patients)
OXYCONTIN (548 patients)
XANAX (547 patients)
ZOCOR (543 patients)
METOPROLOL TARTRATE (539 patients)
CYTARABINE (526 patients)
DECADRON (524 patients)
AMLODIPINE (523 patients)
LEVOTHYROXINE SODIUM (520 patients)
LETAIRIS (518 patients)
PREVACID (517 patients)
CISPLATIN (517 patients)
ADVAIR DISKUS 100/50 (513 patients)
IBUPROFEN (512 patients)
METHYLPREDNISOLONE (504 patients)
SOLU-MEDROL (495 patients)
DIANEAL (493 patients)
DURAGESIC-100 (490 patients)
VELCADE (489 patients)
ETOPOSIDE (486 patients)
PROGRAF (485 patients)
ACYCLOVIR (479 patients)
COREG (478 patients)
LOVENOX (473 patients)
CELEBREX (472 patients)
PRILOSEC (470 patients)
FLUCONAZOLE (468 patients)
METFORMIN HCL (448 patients)
ZOLOFT (442 patients)
AREDIA (441 patients)
OXYGEN (440 patients)
LANSOPRAZOLE (433 patients)
CIPROFLOXACIN (423 patients)
AVANDIA (422 patients)
ENBREL (421 patients)
NITROGLYCERIN (410 patients)
LANTUS (409 patients)
TOPROL-XL (406 patients)
MYCOPHENOLATE MOFETIL (404 patients)
FORTEO (404 patients)
LEUCOVORIN CALCIUM (400 patients)
VINCRISTINE (398 patients)
THALOMID (396 patients)
OXYCODONE HCL (393 patients)
ATROVENT (392 patients)
FAMOTIDINE (392 patients)
TAXOTERE (388 patients)
REGLAN (382 patients)
SPIRONOLACTONE (374 patients)
DIOVAN (373 patients)
ZANTAC (365 patients)
LOPRESSOR (364 patients)
COMBIVENT (362 patients)
VICODIN (362 patients)
LYRICA (362 patients)
TACROLIMUS (359 patients)
PANTOPRAZOLE (359 patients)
NEORAL (359 patients)
METOPROLOL (357 patients)
SINGULAIR (352 patients)
GABAPENTIN (350 patients)
PERCOCET (344 patients)
ALPRAZOLAM (343 patients)
RITUXIMAB (341 patients)
PEPCID (339 patients)
DOXORUBICIN HCL (336 patients)
VITAMIN D (336 patients)
COLACE (334 patients)
OXALIPLATIN (332 patients)
CLONAZEPAM (330 patients)
LEVOFLOXACIN (327 patients)
DIAZEPAM (326 patients)
AMIODARONE HCL (324 patients)
CYMBALTA (323 patients)
LEXAPRO (319 patients)
LORTAB (317 patients)
BACTRIM (317 patients)
RISPERDAL (316 patients)
ALDACTONE (314 patients)
TYLENOL (308 patients)
METRONIDAZOLE (308 patients)
MORPHINE SULFATE (307 patients)
RANITIDINE (305 patients)
ZYPREXA (305 patients)
TYLENOL (CAPLET) (305 patients)
AMOXICILLIN (301 patients)
MEROPENEM (301 patients)
DIFLUCAN (299 patients)
MYOZYME (294 patients)
FLAGYL (294 patients)
PROPOFOL (293 patients)
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% (293 patients)
PREDONINE (292 patients)
AVONEX (292 patients)
PACLITAXEL (289 patients)
TRAMADOL HCL (287 patients)
CALCIUM (286 patients)
ENALAPRIL MALEATE (285 patients)
GLEEVEC (281 patients)
AVASTIN (280 patients)
CLOZARIL (278 patients)
MAGNESIUM OXIDE (277 patients)
SODIUM CHLORIDE (275 patients)
MULTI-VITAMINS (275 patients)
GLYBURIDE (275 patients)
ONDANSETRON (274 patients)
COMPAZINE (274 patients)
DILAUDID (272 patients)
ROCEPHIN (271 patients)
ALBUMIN (HUMAN) (270 patients)
METOCLOPRAMIDE (270 patients)
ARANESP (270 patients)
BACLOFEN (268 patients)
BENADRYL (266 patients)
VITAMIN B-12 (265 patients)
NYSTATIN (263 patients)
KETEK (263 patients)
MULTI-VITAMIN (262 patients)
VORICONAZOLE (261 patients)
BEVACIZUMAB (260 patients)
CARVEDILOL (260 patients)
PANTOPRAZOLE SODIUM (260 patients)
CLARITHROMYCIN (256 patients)
ASCORBIC ACID (256 patients)
CRESTOR (256 patients)
CELLCEPT (251 patients)
REVATIO (244 patients)
EXJADE (243 patients)
HYDROCORTISONE (242 patients)
AMITRIPTYLINE HCL (242 patients)
CELEXA (241 patients)
VITAMIN TAB (240 patients)
CARDIZEM (239 patients)
NEUPOGEN (239 patients)
DOCETAXEL (238 patients)
ACTOS (237 patients)
MAGNESIUM SULFATE (234 patients)
GEMZAR (232 patients)
EFFEXOR (229 patients)
GLIPIZIDE (225 patients)
THEOPHYLLINE (225 patients)
PROMETHAZINE (224 patients)
CLONIDINE (222 patients)
TRAZODONE HCL (222 patients)
ZITHROMAX (221 patients)
AZATHIOPRINE (221 patients)
RAMIPRIL (219 patients)
VALIUM (217 patients)
TAXOL (217 patients)
COZAAR (216 patients)
IRESSA (216 patients)
ARAVA (216 patients)
IPRATROPIUM BROMIDE (214 patients)
ZYRTEC (213 patients)
GLUCOPHAGE (212 patients)
FERROUS SULFATE TAB (212 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about RESPIRATORY FAILURE and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.